

February 11, 2015



# Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015

**Live Audio Webcast on Wednesday, February 11, at 3:05 p.m. EST**

NORWOOD, MA -- (Marketwired) -- 02/11/15 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, [Resunab](#)<sup>™</sup>, for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it is presenting at the 2015 Leerink Global Healthcare Conference on February 11, 2015, at 3:05 p.m. EST the Waldorf Astoria in New York, New York.

Yuval Cohen, Ph.D., Chief Executive Officer, will participate in a fireside chat question and answer session regarding the Company and its clinical development plans for Resunab, a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity, under clinical development for cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (scleroderma).

A live audio webcast will be available by accessing the [IR Calendar](#) in the [Investors](#) section of the Corbus Pharmaceuticals website ([www.CorbusPharma.com](http://www.CorbusPharma.com)). The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

## ***About Resunab***<sup>™</sup>

Resunab<sup>™</sup> is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."

## ***About Corbus Pharmaceuticals***

Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate Resunab<sup>™</sup> is a novel oral specialized pro-resolving mediator anti-inflammatory drug scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis ("Scleroderma") in 2015. For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com).

### ***Forward-Looking Statements***

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

### ***Investor and Media Contact***

Jenene Thomas

Investor Relations and Corporate Communications Advisor

Jenene Thomas Communications, LLC

Phone: +1 (908) 938-1475

Email: [Email Contact](#)

Source: Corbus Pharmaceuticals Holdings, Inc.